Article
Targeting cancer with small molecule pan-KRAS degraders
2023-10-26
Abstract excerpt
Despite the high prevalence of cancers driven by KRAS mutations, to date only the G12C mutation has been clinically proven to be druggable via covalent targeting of the mutated cysteine amino acid residue (1). However, in many cancer indications other KRAS mutations, such as G12D and -V, are far more prevalent and small molecule concepts that can address a wider variety of oncogenic KRAS alleles are in high clinic...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- c329542b-11ba-5475-a443-85c4c5c96c98
- DOI
- 10.1101/2023.10.24.563163